文献速递中枢神经肿瘤放疗头颈部肿瘤放疗

阿帕替尼治疗头颈部肿瘤患者放射性脑损伤的疗效与安全性:一项开放标签、单臂、2期研究

Efficacy and Safety of Apatinib for Radiation-induced Brain Injury Among Patients With Head and Neck Cancer: An Open-Label, Single-Arm, Phase 2 Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-04-01

这项2期开放标签单臂前瞻性研究纳入36例头颈部肿瘤放疗后新诊断放射性脑损伤的患者,口服阿帕替尼250 mg每日一次共4周。第4周总体临床有效率为61.1%(95% CI 43.5%-76.9%),31例脑坏死病灶患者中19例(61.3%)改善,未出现治疗相关4至5级毒性。

要点

  • 36例可评估患者中22例(61.1%)在第4周达到主要终点,即MRI FLAIR脑水肿体积较基线缩小≥25%。
  • 31例脑坏死病灶患者中19例(61.3%)脑坏死改善。
  • 最常见1至2级不良事件为手足综合征、乏力和高血压,无治疗相关4至5级毒性。

核心结论

  • 口服阿帕替尼在放射性脑损伤患者中显示出有前景的疗效且耐受性良好,需进一步随机对照研究。

研究设计与样本

  • 2期开放标签单臂前瞻性研究,在中国中山大学孙逸仙纪念医院招募35至80岁、有头颈部肿瘤放疗史且新诊断放射性脑损伤的患者。
  • 阿帕替尼250 mg每日一次口服共4周,采用Simon极小极大两阶段设计。
  • 共筛查37例,2019年10月17日至2020年8月3日入组36例,第1阶段19例、第2阶段17例,36例均纳入疗效和安全性评估。

主要发现

  • 36例可评估患者中22例(61.1%;95% CI 43.5%-76.9%)在第4周达到主要终点,即MRI FLAIR脑水肿体积较基线缩小≥25%。
  • 31例脑坏死病灶患者中19例(61.3%;95% CI 42.2%-78.2%)脑坏死改善。
  • 最常见1至2级不良事件为手足综合征、乏力和高血压,无治疗相关4至5级毒性。

关键数值与推荐

  • 主要终点为第4周MRI FLAIR图像上脑水肿体积较基线缩小≥25%的总体临床有效率。
  • 次要终点包括脑坏死总体改善率、神经功能和安全性的改善率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步随机对照研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The treatment of radiation-induced brain injury (RI) caused by radiation therapy for head and neck cancer is challenging. Antiangiogenic therapy is a promising treatment. Apatinib is an oral tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2. We aimed to assess the efficacy and safety of apatinib in patients with RI. METHODS AND MATERIALS: In this phase 2, open-label, single-arm, prospective study, we recruited patients aged 35 to 80 years with prior radiation therapy history for head and neck cancer who had newly diagnosed RI at the Sun Yat-sen Memorial Hospital, China. Apatinib was administered at a dosage of 250 mg once daily orally for 4 weeks. A Simon minimax 2-stage design was performed. The primary outcome was the proportion of patients with overall clinical efficacy, defined as a radiographic response of ≥25% reduction in baseline brain edema volume on magnetic resonance fluid attenuated inversion recovery images at week 4. Secondary end points were the overall improvement rate of brain necrosis, neurologic function, and safety. RESULTS: We screened 37 patients, 36 of whom were enrolled between October 17, 2019, and August 3, 2020. At the cutoff date, 36 patients were assessed for efficacy and safety (19 were enrolled in stage 1 and 17 in stage 2). Of the 36 patients evaluated for overall clinical efficacy, 22 patients (61.1%; 95% CI, 43.5%-76.9%) achieved the primary end point at week 4. Among the 31 patients with brain necrosis lesions, 19 patients (61.3%; 95% CI, 42.2%-78.2%) showed improvement of brain necrosis. The most common grade 1 to 2 adverse events were hand-foot syndrome, fatigue, and hypertension There were no treatment-related grade 4 to 5 toxic effects. CONCLUSIONS: Oral apatinib shows promising efficacy and is well-tolerated in patients with RI. Further randomized controlled studies are warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. He L, Pi Y, Li Y, et al. Efficacy and Safety of Apatinib for Radiation-induced Brain Injury Among Patients With Head and Neck Cancer: An Open-Label, Single-Arm, Phase 2 Study. Int J Radiat Oncol Biol Phys. 2022. PMID: 35378217. doi:10.1016/j.ijrobp.2022.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。